Skip to main content
. Author manuscript; available in PMC: 2022 May 3.
Published in final edited form as: Clin Cancer Res. 2022 May 2;28(9):1863–1870. doi: 10.1158/1078-0432.CCR-21-3018

Figure 3: Molecular landscape of the MSS subcohort.

Figure 3:

A) Genetic landscape comparison between RSPOfp vs. RNF43-mut tumors in the MSS subgroup. KRAS mutation was the only statistically different genetic alteration. ***q<0.001.

B) TMB and PDL-1 status in RNF43-mut, RSPOfp and RNF43/RSPOfp-WT CRCs. None of the RSPOfp patients showed a TMB >10 mt/Mb or a MSI-H/dMMR status.*q<0.05, **q<0.01, ***q<0.001.

C) Copy number alterations in RNF43 mutations, RSPO rearrangements and RNF43/RSPO-WT samples. *q<0.05.